Biomedical Research in Gynecology : VHIR Annual Report 2020

Oncology

< Back

Overview

In 2020, the Area has been composed by eight groups addressing main unsolved issues in cancer, covering the fields of child and adolescent cancer, melanoma, gynecology, urology, cancer stem cells and molecular mechanisms of the tumor pathologies, as well nanomedicine. We work in close collaboration with the corresponding departments at the Hospital. This provides a unique opportunity to tackle the abovementioned pathologies during the entire course of the disease, from diagnosis (a focus and strength of our Area) to personalized treatment (gathering important international impact during 2020 in the field of child cancer). Our research in 2020 has been relevant also in the field of the use of nanotechnology in biomedical applications to improve therapeutic strategies and diagnostics. Despite, the COVID-19 pandemic, the Area has kept active at virtual shared activities and ONCO-VHIR seminars and the organization of the World Cancer Day event to get closer to the society. During 2020 in-Campus collaborations with VHIO have been strengthen and internalization of our research has been amplified. It is also noteworthy the shared scientific production in terms of publications between different groups of the Area and the stable collaborations between groups that have consolidated during these period.

Publications

174
total
926
impact factor
5.32
average impact factor

Group Leader: Antonio Gil Moreno

The endometrial cancer translational research group has further strength the translation focus of its research in biomarkers and personalized medicine. They won the WildCard program of the EiTHealth to foster the development of a molecular test to diagnose endometrial cancer. Thanks to the large biobank of endometrial cancer PDX models, they have created strategic alliances with pharmaceutical companies to unveil the efficacy of novel treatments in endometrial cancer. In the basic and translational research in ovarian cancer, Dr. Melissa Bradbury has been integrated as new principal researcher of the team. In the endometriosis group, we are unveiling new prognostic biomarkers through transcriptomic and proteomic approaches. In the clinical research group, we conducted multicenter studies through the research network of the Spanish Society of Gynecology and Obstetrics (SEGO), with excellent results.

VHIR Annual Report 2020